RecruitingNCT06588868

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma: an Observational Retrospective Multicenter Study

Sponsor

Fondazione Italiana Linfomi - ETS

Enrollment

400 participants

Start Date

Feb 27, 2025

Study Type

OBSERVATIONAL

Conditions

Cutaneous T Cell Lymphoma Cutaneous T-Cell Lymphoma/Mycosis Fungoides Cutaneous T-Cell Lymphoma/Sezary Syndrome

Summary

The study is designed to describe the different approaches of systemic therapies for the treatment of Cutaneous T-cell Lymphoma in real world setting.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is an observational study (no new treatment) reviewing real-world data from patients with cutaneous T-cell lymphoma (CTCL) — a type of cancer that primarily affects the skin — who received systemic (whole-body) treatments. The goal is to understand how well these treatments have worked in practice. **You may be eligible if...** - You have a confirmed diagnosis of CTCL according to standard diagnostic criteria - You are 18 or older - You received at least one systemic (non-topical) treatment between January 2016 and December 2023 that lasted at least 3 months - Your complete medical records are available for review - You are willing to sign informed consent **You may NOT be eligible if...** - You do not meet the above criteria - You refuse to sign the consent form Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(18)

AOU Ospedali Riuniti delle Marche - Clinica di Ematologia

Ancona, Italy

IRCCS Istituto Tumori Giovanni Paolo II - U.O.C. Ematologia

Bari, Italy

U.O.C. Dermatologia e Venereologia Universitaria - A.O.U. Policlinico Consorziale

Bari, Italy

Policlinico S.Orsola-Malpighi - Istituto di Ematologia

Bologna, Italy

ASST Spedali Civili di Brescia - S.C. Ematologia

Brescia, Italy

A.O. Brotzu Ospedale Businco - S.C. Ematologia e CTMO

Cagliari, Italy

A.O.U. Policlinico S. Marco - U.O.C. di Ematologia

Catania, Italy

Unità funzionale di Ematologia - Azienda Ospedaliera Universitaria Careggi

Florence, Italy

S.C. Dermatologia - E.O. Galliera

Genova, Italy

Oncoematologia - ASST Fatebenefratelli - Sacco

Milan, Italy

U.O.C. Dermatologia - Ospedale Maggiore Policlinico Fondazione IRCCS Ca' Granda

Milan, Italy

U.O.C. Clinica Dermatologica - A.O.U. di Padova

Padova, Italy

U.O.C Ematologia 1 - IRCCS Fondazione Policlinico San Matteo

Pavia, Italy

IRCCS I.F.O. San Gallicano - UOSD Porfirie e Malattie Rare

Roma, Italy

Skin Cancer Center - IRCCS Istituto Dermopatico dell'Immacolata

Roma, Italy

U.O.C. Dermatologia - A.O.U. Senese

Siena, Italy

A.O.U. Città della Salute e della Scienza di Torino - S.C. Dermatologia U

Torino, Italy

A.O.U.I. di Verona - U.O.C. Ematologia

Verona, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06588868

Related Trials

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

Conditions

Summary

Eligibility

Plain Language Summary

Locations(18)

Related Trials

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

Photopheresis in Early-stage Mycosis Fungoides

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL